IDEAYA Biosciences, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IDEAYA Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $922.00K, a 12.44% increase year-over-year.
- IDEAYA Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $673.00K, a 2.28% increase year-over-year.
- IDEAYA Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- IDEAYA Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $820.00K, a 4.99% increase year-over-year.
- IDEAYA Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.49M, a 3.75% increase from fiscal 2024.
- IDEAYA Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.44M, a 18.63% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $1.21M, a 60.66% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $755.00K, a 8.32% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $922.00K 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $673.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $1.49M 10-K · filed 2026-02-17 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | |
| 2025-06-30 | $820.00K 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $658.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $1.44M 10-K · filed 2026-02-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | |
| 2024-06-30 | $781.00K 10-Q · filed 2025-08-05 | |
| 2023-12-31 | $576.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $1.21M 10-K · filed 2026-02-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | |
| 2023-06-30 | $637.00K 10-Q · filed 2024-08-06 | |
| 2022-12-31 | $320.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $755.00K 10-K · filed 2025-02-18 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | |
| 2022-06-30 | $435.00K 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $370.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $697.00K 10-K · filed 2024-02-20 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | |
| 2021-06-30 | $327.00K 10-Q · filed 2022-08-15 | |
| 2020-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $326.00K 10-K · filed 2023-03-07 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | |
| 2020-06-30 | $132.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |